Phage Biomanufacturing Company GenoFarm Bio Completes Tens of Millions RMB Pre-A Financing Round

VCBeat has learned that, recently, the bacteriophage biomanufacturing industry platformGridRuinong BiotechAnnounced the completion of a tens-of-millions-yuan Pre-A financing round, led byShenzhen Huibo Growth Venture CapitalExclusive Investment,WinX CapitalServing as the exclusive long-term financial advisor. The proceeds from this financing round will primarily be used to accelerate product innovation for multi-scenario applications of bacteriophages, regulatory filings, and related activities. The Pre-A+ financing round is currently underway.

Greenon was founded at a critical juncture in China’s campaign to reduce and restrict antibiotic use. Against the backdrop of increasingly prominent misuse of antibiotics in animal husbandry and stagnant progress in the development of alternative drugs, the Ministry of Agriculture and Rural Affairs of ChinaJuly 2020It was mandated that all antimicrobial feed additives be completely phased out. Subsequently, the government issued another document emphasizing that by the end of 2025, more than 50% of large-scale livestock farms would implement initiatives to reduce antibiotic use in animal husbandry.

On August 23, 2021, six ministries and commissions jointly issued the "14th Five-Year Plan for National Agricultural Green Development," which stated that during the 14th Five-Year Plan period, agricultural development would enter a new stage of accelerating comprehensive green transformation, with solid progress in reducing chemical pesticide use. On November 18, 2022, the Ministry of Agriculture and Rural Affairs issued the "Action Plan for Reducing Chemical Pesticide Use by 2025," proposing to vigorously promote biological control, popularize the application of plant-derived pesticides, microbial pesticides, and fermented biopesticides, and gradually reduce the intensity of chemical pesticide use. On December 27, 2024, Document No. 27 (2024) of the Ministry of Agriculture and Rural Affairs pointed out that by 2030, biological control and green prevention and control using high-efficiency, low-risk pesticides would be incorporated into unified prevention and control services, with the coverage rate of green prevention and control for major crops exceeding 60%, and the unified control coverage rate for the three major grain crops exceeding 50%. On December 13, 2024, Document No. 51 (2024) of the Hubei Provincial People's Government indicated that the agricultural micro-production industry is a strategic emerging industry and a new quality productive force that urgently needs focused cultivation, holding significant importance for safeguarding national food security and promoting green agricultural development.

GreenAgri has consistently adhered to a path of independent innovation. As early as 2022, the company established a top-tier scientific research team in the field of plant protection, leveraging bacteriophage technology to focus on the development of products targeting bacterial plant diseases. After two years of market research and technological breakthroughs, GreenAgri successfully industrialized its bacteriophage product series, including “Xiao Qing Ning” and “Kui Yang Ning,” for major plant diseases such as bacterial wilt and canker in 2024. These plant protection products were officially launched to the market this year. Driven by innovation, GreenAgri provides novel biological control solutions for plant health, reducing the use of chemical pesticides, minimizing environmental pollution, and supporting sustainable agricultural development.

Greennon provides its partners with more precise and efficient bacteriophage solutions, currently serving numerous leading livestock enterprises such as New Hope Group, Wens Foodstuff Group, Fengxiang Group, Hefeng Group, and Shengfeng. With continuous business expansion and sustained growth in market share, Greenon’s revenue has demonstrated strong momentum, achieving a year-on-year increase of nearly 100% in 2024.

Amid growing global calls for environmental protection and food safety, the United Nations Environment Programme (UNEP) adopted a new framework agreement at the ICCM5 meeting held in September 2023, urging the phased elimination of high-hazard pesticides in agriculture by 2035 and a transition to safer and more sustainable chemical pesticide alternatives. This year, GreenAgri established its Overseas Business Division to leverage its technological and product quality advantages in meeting the global demand for “green agriculture,” actively expanding into international markets in South America, Southeast Asia, and other regions, thereby advancing the globalization of Chinese bacteriophage technology.

Greennong Biotechnology will deepen its expertise in the field of phage technology, striving to become a globally leading industrial platform for phage-based biomanufacturing and contributing to the global human health industry.

Xie Weijing, Shenzhen Huibo Growth Venture CapitalIt is indicated that bacteriophages, characterized by high host specificity and low residual risk, represent an ideal approach for bacterial control. Leveraging extensive technological expertise, the GreenAgri team has conducted high-throughput screening of its vast bacteriophage library by integrating genomics and structural biology. Its proprietary “Super Cocktail” technology and combination regimens of bacteriophages with antibiotics have garnered strong recognition from numerous large-scale livestock farming groups. We remain firmly optimistic about the broad application of bacteriophage technology in antibiotic substitution and reduction, and look forward to GreenAgri leading the next-generation revolution of bacteriophage technology in the fields of animal health, plant protection, food safety, and consumer healthcare.

WinX CapitalWinX Capital is honored to have supported Grainon Biotech in closing another round of financing. Grainon Biotech’s strong revenue growth and profitability over the past year fully demonstrate the company’s market potential and competitiveness. Leveraging its robust R&D capabilities and competitive product portfolio, the company has successfully seized the historic opportunity presented by national initiatives to reduce and replace antibiotic use, emerging as a standout enterprise in China’s bio-agriculture sector. We believe that under the leadership of Professor Wang Xiliang’s team, Grainon will continue to maintain strong momentum, contributing to food safety and sustainable development in China.

As the specialized equity investment and fund management platform under Shenzhen Guarantee Group, Shendan Venture Capital is committed to providing innovative financial services that combine direct and indirect financing for enterprises. It has deeply deployed in the “20+8” industrial sectors to support technological innovation. With a registered capital of RMB 1 billion and assets under management nearing RMB 5 billion, Shendan Venture Capital has made over 200 historical investments, covering strategic emerging industries such as next-generation electronic information, new materials, high-end equipment manufacturing, biomedicine, and green low-carbon technologies. In early-stage investment, Shendan Venture Capital has initiated and established talent funds and angel funds, patiently accompanying the growth of technology-based small and medium-sized enterprises.

WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in Healthcare for 2024,” Diyixinsheng’s “No. 1 Financial Advisory Firm in Healthcare for 2022 and 2023,” and VCBeat’s “Annual Healthcare Financial Advisor” as part of the “Future Healthcare 100” list from 2022 to 2024.